TLSI:NSD-TriSalus Life Sciences Inc. (USD)

COMMON STOCK | Medical Devices |

Last Closing

USD 9.83

Change

+0.11 (+1.13)%

Market Cap

USD 0.26B

Volume

0.01M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-18 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
DXCM DexCom Inc

-1.51 (-1.19%)

USD 49.24B
ALGN Align Technology Inc

+2.14 (+0.76%)

USD 21.26B
SWAV Shockwave Medical Inc

-0.35 (-0.11%)

USD 12.34B
BRKR Bruker Corporation

+1.02 (+1.31%)

USD 11.77B
PODD Insulet Corporation

-1.67 (-0.97%)

USD 11.64B
MASI Masimo Corporation

-0.40 (-0.30%)

USD 7.20B
IRTC iRhythm Technologies Inc

+2.16 (+1.97%)

USD 3.48B
AXNX Axonics Modulation Technologie..

+0.30 (+0.45%)

USD 3.40B
TMDX TransMedics Group Inc

+23.47 (+24.93%)

USD 3.02B
LIVN LivaNova PLC

+6.87 (+12.32%)

USD 3.00B

ETFs Containing TLSI

TADS 4.26 % 0.00 %

N/A

N/A
SLYV SPDR® S&P 600 Small Cap .. 0.72 % 0.15 %

+0.35 (+0%)

USD 4.00B
VIOV Vanguard S&P Small-Cap 60.. 0.71 % 0.20 %

+0.26 (+0%)

USD 1.28B

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 16.33% 81% B- 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.33% 81% B- 83% B
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 0.26B 62% D 52% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector